Abstract Number: 0535 • ACR Convergence 2024
Oral Glucocorticoid Premedication Is at Least as Effective as Intravenous Glucocorticoid Premedication for Prevention of Infusion-related Reactions to Rituximab in Rheumatoid Arthritis Patients
Background/Purpose: It has been demonstrated that pretreatment with intravenous glucocorticoids can prevent infusion-related reactions (IRR) that may occur in RA patients receiving rituximab infusions [1].…Abstract Number: 0708 • ACR Convergence 2024
Outcomes of Intermittent Intravenous Steroid Use During Infusion Therapy in Systemic Sclerosis
Background/Purpose: Use of high dose corticosteroids in systemic sclerosis (SSc) is considered a significant risk factor for development of scleroderma renal crisis (SRC). Intravenous (IV)…Abstract Number: 1025 • ACR Convergence 2024
Gender Disparities in Disease Impact and Treatment Access for Spondyloarthropathies in Latin America: Insights from a Web Survey
Background/Purpose: Previous studies have shown that female patients with spondyloarthritis (SpA) tend to experience a greater impact on their functionality, especially among women in Latin…Abstract Number: 1386 • ACR Convergence 2024
Olokizumab in Real Clinical Practice: Efficacy and Safety
Background/Purpose: Olokizumab (OKZ) is a direct inhibitor of interleukin 6, which has shown significant symptom reduction in RA patients, however there is a lack of…Abstract Number: 1492 • ACR Convergence 2024
Timing of SLEDAI-2K Item Improvements During the First Year of Intravenous Anifrolumab Treatment of Moderate to Severe SLE
Background/Purpose: SLE is a chronic disease in which irreversible organ damage can accumulate over time; treatments associated with rapid responses in patients are therefore desirable.1…Abstract Number: 1860 • ACR Convergence 2024
Targeting Th1 Effector Cytokines, TNF-α and IFN-γ, Attenuates Experimental Autoimmune Myeloperoxidase ANCA Associated Vasculitis
Background/Purpose: Anti-cytokine monoclonal antibody (mAb) therapies have shown efficacy in numerous autoimmune diseases but have yet to succeed in myeloperoxidase anti-neutrophil cytoplasmic antibody associated vasculitis…Abstract Number: 2084 • ACR Convergence 2024
Efficacy and Safety of a Step-down Regimen of Low Dosage of Glucocorticoids Combined with Early Administration of Synthetic or Biologic Immunosuppressants in Anti-synthetase Syndrome: A Pilot Study
Background/Purpose: Anti-synthetase syndrome (ASS) is a rare autoimmune disease characterized by the presence of anti-aminoacyl-transfer-RNA synthetase antibodies (ARS) and the involvement of muscles, skin, joints,…Abstract Number: 2359 • ACR Convergence 2024
A Real-World Study on the Clinical Characteristics and Patient Reported Outcomes of Patients with Active AxSpA Prescribed CT-P13 SC in Five European Countries
Background/Purpose: CT-P13 SC, a new formulation of infliximab administered subcutaneously, has been approved by European Medicine Agency for the treatment of radiographic axial spondylarthritis (axSpA)…Abstract Number: 2586 • ACR Convergence 2024
Results from the Biopsy Driven Ebio Study: Entheseal Tissue Signature in Response to IL-17 Blockade in Psoriatic Arthritis
Background/Purpose: Enthesitis is considered to be an early event in psoriatic arthritis (PsA) course, representing a hallmark feature of the disease. So far, most of…Abstract Number: L14 • ACR Convergence 2023
Efficacy and Safety of Benralizumab Compared with Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Patients Receiving Standard of Care Therapy: Phase 3 MANDARA Study
Background/Purpose: Eosinophilic inflammation is a key pathophysiological mechanism of eosinophilic granulomatosis with polyangiitis (EGPA). Oral glucocorticoids (OGCs) and immunosuppressants remain the basis for the standard…Abstract Number: L08 • ACR Convergence 2023
Early Clinical Development of CIT-013, a First in Class NETosis Inhibitor, in a Randomized Phase I Dose Escalation Study in Healthy Volunteers Demonstrating Potent Inhibition of LPS Induced Neutrophil Extracellular Trap Formation
Background/Purpose: Aberrant Neutrophil Extracellular Traps (NETs) production contributes to the pathophysiology of multiple inflammatory and autoimmune diseases such as Rheumatoid arthritis (RA) Hidradenitis suppurativa (HS),…Abstract Number: L11 • ACR Convergence 2023
Risk of Cardiovascular Events According to Biological Agent Exposure in Patients with Ankylosing Spondylitis: A Korean Population-based Study
Background/Purpose: Patients with ankylosing spondylitis (AS) have a higher risk of cardiovascular events than controls. Although biological disease-modifying anti-rheumatic drugs (bDMARDs) are efficacious in treating…Abstract Number: 0050 • ACR Convergence 2023
Anti-Citrullinated Histone Antibody CIT-013, a Dual Action Therapeutic for Neutrophil Extracellular Trap Associated Autoimmune Disease
Background/Purpose: Neutrophil extracellular traps (NETs) contribute to the pathophysiology of multiple inflammatory and autoimmune diseases (Chirivi et al., 2021; DOI: 10.1038/s41423-020-0381-3). Targeting the NETosis pathway…Abstract Number: 0384 • ACR Convergence 2023
Targeting NET Formation in Early RA Patients; A Spin-off Study from the NORD-STAR
Background/Purpose: The formation of neutrophil extracellular traps (NETs) with extrusion of nuclear, granular and cytosolic components from a dying neutrophil, has been described extensively in…Abstract Number: 0522 • ACR Convergence 2023
Effect of Secukinumab versus Adalimumab Biosimilar on Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis: Results from Subgroup Analyses by Baseline Syndesmophytes and C-reactive Protein Status
Background/Purpose: SURPASS, a phase 3b randomized controlled study in patients with radiographic axial spondyloarthritis (r-axSpA), found low spinal radiographic progression over 2 years with no…
- « Previous Page
- 1
- …
- 23
- 24
- 25
- 26
- 27
- …
- 67
- Next Page »